Faes Farma S.A. Logo

Faes Farma S.A.

Develops and markets pharmaceuticals, like antihistamines, and animal nutrition products globally.

FAE | MC

Overview

Corporate Details

ISIN(s):
ES0134950F36
LEI:
959800FXZQY7U3P1G969
Country:
Spain
Address:
AVENIDA AUTONOMIA, 10-, 48940 Leioa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Faes Farma S.A. is an international pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceuticals and animal nutrition products. With a history of over 90 years, the company operates two main business lines. The pharmaceutical division focuses on therapeutic areas such as allergies, gastroenterology, and immunology, with key proprietary molecules including the antihistamine Bilastine and Vitamin D treatment Calcifediol. The animal nutrition division provides specialized feeds and nutritional solutions, particularly for swine, through brands like Ingaso Farm and Tecnovit. The company emphasizes innovation through significant R&D investment and has a global presence with direct commercial operations across Europe, Latin America, Africa, and the Middle East.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Faes Farma S.A. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-16 00:00
Post-Annual General Meeting Information
Acuerdo Junta Extraordinaria de Accionistas
Spanish 115.9 KB
2025-06-25 00:00
Post-Annual General Meeting Information
Aspectos relevantes de la Junta de Accionistas 2025
Spanish 159.0 KB
2025-06-25 00:00
Investor Presentation
Presentación Junta de Accionistas 2025
Spanish 4.2 MB
2025-06-11 00:00
Pre-Annual General Meeting Information
Junta General Extraordinaria de Accionistas
Spanish 167.3 KB
2025-05-19 15:51
Pre-Annual General Meeting Information
Convocatoria de la Junta General de Accionistas de 2025
Spanish 180.2 KB
2025-05-19 00:00
Pre-Annual General Meeting Information
Convocatoria de la Junta General de Accionistas de 2025
Spanish 180.2 KB
2025-05-06 08:25
Investor Presentation
Informe de negocio del primer trimestre de 2025
Spanish 1.7 MB
2025-04-29 16:08
Report Publication Announcement
Faes Farma anuncia la celebración de un webcast para presentar los resultados d…
Spanish 65.2 KB
2025-04-22 11:39
Investor Presentation
Presentación Capital Markets Day 2025
Spanish 4.7 MB
2025-04-22 09:56
Investor Presentation
La Sociedad comunica que hoy celebrará su Capital Markets Day para presentar el…
Spanish 55.7 KB
2025-03-25 18:09
M&A Activity
Faes Farma S.A. ha suscrito un contrato para la adquisición de Laboratorios Edo…
Spanish 67.7 KB
2025-02-28 07:55
Investor Presentation
Informe de negocio y resultados 2024
Spanish 1.2 MB
2025-02-28 07:52
Major Shareholding Notification
La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2024
Spanish 426.0 KB
2025-02-28 07:51
Remuneration Information
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
Spanish 213.3 KB
2025-02-28 00:00
Annual / Quarterly Financial Statement
Spanish 12.1 MB

Automate Your Workflow. Get a real-time feed of all Faes Farma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Faes Farma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.